Salivary gland carcinoma (SGC) is a relatively uncommon malignancy. In many articles only a few patients could be included and the data are insufficient to conclude that combination therapy is superior to single-agent therapy. There is no clear evidence to establish a recommended regimen as the standard treatment. To summarize previous reports, in single-agent therapy, objective responses were observed in 21/158 patients, 13% of adenoid cystic carcinoma (ACC), 9/36 patients, 25% of mucoepidermoid carcinoma (MEC), and 15/42 patients, 36% of adenocarcinoma (ADC). Cisplatin-anthracycline-5FU-based combination regimens also had activity in 36/127 patients, 28% of adenoid cystic carcinoma (ACC), 10/22 patients, 45% of mucoepidermoid carcinoma (MEC), and 19/39 patients, 49% of adenocarcinoma (ADC). Combination chemotherapy regimens have demonstrated higher response rates compared with single-agent therapy but there are no differences in the response duration, survival time and mean survival time (MST) among these two groups. In our study of concurrent chemoradiotherapy with CDDP/5FU, 17/19 patients, 89.5% were completed with the planned treatment. The response rate was 100% (10 cases of PR). 3-year overall survival rate and progression-free survival rate were 76.9% and 66.9%. In 10 cases of ACC, the mean disease-free time and survival time were 37.1 months (14.1-77.8) and 39.1 months (14.1-77.8). All patients of ACC were alive, including 2 patients with disease. Concurrent chemoradiotherapy can improve the overall survival rate of SGC.